ReviewCell host & microbe2008
Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development.
Review in Cell host & microbe, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 175 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
175 citing papers in PubMed, 1 synthesis or guideline pooled it, 277 citations in OpenAlex.
- Meta-analysis of all immune epitope data in the Flavivirus genus: inventory of current immune epitope data status in the context of virus immunity and immunopathology.Viral immunology · 2010Pooled it
- Impact of Pre-exposure History and Host Genetics on Antibody Avidity Following Norovirus Vaccination.The Journal of infectious diseases · 2017Trial
- Nanoparticle vaccine formulations for dengue virus.RSC pharmaceutics · 2026Review
- Multiple, but not isolated, yellow fever virus-associated orthoflavivirus immune histories drive antibody-dependent enhancement of Zika and dengue viruses.medRxiv : the preprint server for health sciences · 2026Article
- Protective human antibodies against Powassan virus.Journal of virology · 2026Article
- Targeting the Zika virus envelope domains I and III as a recombinant vaccine protects mice from lethal challenge.NPJ vaccines · 2026Article
- Potent Monoclonal Antibodies Against Circulating Yellow Fever Virus Strains from Donors Immunized with the 17D Vaccine.The American journal of tropical medicine and hygiene · 2026Article
- LRP8 is an entry receptor for tick-borne encephalitis viruses.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Article
- Engineered antibody-mediated broad-spectrum suppression of human arboviruses in the Aedes aegypti vector.Communications biology · 2025Article
- Mature dengue virus particles inactivated by a non-ionic detergent retain quaternary neutralizing epitopes and induce potent neutralizing antibodies.Frontiers in immunology · 2025Article
- Neutralization Tests for Quantification of Specific Antibodies Against Yellow Fever Virus.Methods in molecular biology (Clifton, N.J.) · 2025Article
- A bivalent self-amplifying RNA vaccine against yellow fever and Zika viruses.Frontiers in immunology · 2025Article
- Envelope domain III EJournal of virology · 2024Article
- Modelling the mechanisms of antibody mixtures in viral infections: the cases of sequential homologous and heterologous dengue infections.Journal of the Royal Society, Interface · 2024Article
- Characterisation of a Japanese Encephalitis virus genotype 4 isolate from the 2022 Australian outbreak.Npj viruses · 2024Article
- Epitope(s) involving amino acids of the fusion loop of Japanese encephalitis virus envelope protein is(are) important to elicit protective immunity.Journal of virology · 2024Article
- Antibody and Cell-Based Therapies against Virus-Induced Cancers in the Context of HIV/AIDS.Pathogens (Basel, Switzerland) · 2023Review
- Utility of an In-Vitro Micro-Neutralizing Test in Comparison to a Plaque Reduction Neutralization Test for Dengue Virus, Japanese Encephalitis Virus, and Zika Virus Serology and Drug Screening.Pathogens (Basel, Switzerland) · 2023Article
- Review
115 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Flaviviruses are a group of small RNA viruses that cause severe disease in humans worldwide and are the target of several vaccine development programs. A primary goal of these efforts is to elicit a protective humoral response directed against the envelope proteins arrayed on the surface of the flavivirus virion. Advances in the structural biology of these viruses has catalyzed rapid progress toward understanding the complexity of the flavivirus immunogen and the molecular basis of antibody-mediated neutralization. These insights have identified factors that govern the potency of neutralizing antibodies and will inform the design and evaluation of novel vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.